Randomized , Double-Blind , Placebo-Controlled , Phase I 11 Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as Adjunct to Induction Treatment of High-Grade Malignant Non-Hodgkin ' s Lymphomas

By Heinrich H. Gerhartz, Marianne Engelhard, Peter Meusers, Gunter Brittinger, Wolfgang Wilmanns, Gilnther Schlimok, Peter Mueller, Dieter Huhn, Reinhard Musch, Wolfgang Siegert, Diana Gerhartz, Joachim H. Hartlapp, Eckhard Thiel, Christoph Huber, Christian Peschl, Wolfgang Spann, Bertold Emmerich, Christine Schadek, Martin Westerhausen, Hans-Wilhelm Pees, Hartmut Radtke, Andreas Engert, Elke Terhardt, Hans Schick, Thomas Binder, Roland Fuchs, JOrg Hasford, Roland Brandmaier, Angelika C. Stern, Thomas C. Jones, Hartmut J. Ehrlich, Harald Stein, Mohamed Parwaresch, Markus Tiemann, and Karl Lennert

[1]  R. Fisher,et al.  A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Gerhartz,et al.  Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy. , 1993, Leukemia research.

[3]  L. Gordon,et al.  Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[4]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[5]  W. Fibbe,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. , 1992, Blood.

[6]  N. Nissen,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Bennett,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. , 1992, Annals of internal medicine.

[8]  I. Fabian,et al.  Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. , 1991, Experimental hematology.

[9]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[10]  J. Armitage,et al.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.

[11]  M. Engelhard,et al.  Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Tiley,et al.  Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial , 1990, The Lancet.

[13]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[14]  F. Herrmann,et al.  Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. , 1990, The American journal of medicine.

[15]  R A Olshen,et al.  Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Haanen,et al.  Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W Koepcke,et al.  Analyses of group sequential clinical trials. , 1989, Controlled clinical trials.

[18]  S. Jagannath,et al.  Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. , 1989, Blood.

[19]  B. Coiffier,et al.  Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. , 1989, Blood.

[20]  B. Kushner,et al.  GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. , 1989, Blood.

[21]  R. Widen,et al.  Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3. , 1989, Blood.

[22]  F. Herrmann,et al.  Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. , 1989, The Journal of clinical investigation.

[23]  A. Burgess,et al.  Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. , 1989, Annals of internal medicine.

[24]  F. Herrmann,et al.  Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Socinski,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.

[26]  D. Longo,et al.  The role of chemotherapy in diffuse aggressive lymphomas. , 1988, Seminars in hematology.

[27]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[28]  K. Lennert,et al.  Updated Kiel classification for lymphomas , 1989, The Journal of pathology.

[29]  W. Hryniuk.  The importance of dose intensity in the outcome of chemotherapy. , 1988, Important advances in oncology.

[30]  R. Fisher,et al.  Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. , 1988, Seminars in hematology.

[31]  D. Golde,et al.  Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. , 1986, Blood.

[32]  J. Gabrilove,et al.  Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. , 1986, Science.

[33]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Nagata,et al.  Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor , 1986, Nature.

[35]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[36]  G. Brittinger,et al.  Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group , 1984, Hematological oncology.

[37]  M. Pasmantier,et al.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.